The research advance of fibroblast growth factor 21 in anti-atherosclerosis
10.7507/1007-4848.201801013
- VernacularTitle:成纤维细胞生长因子 21 抗动脉粥样硬化的研究进展
- Author:
XIE Yong
1
;
LI Dongze
1
;
LI Fanghui
2
;
LU Guangwen
3
;
CAO Yu
1
Author Information
1. Department of Emergency Medicine, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China
2. West China School of Medicine, Sichuan University, Chengdu, 610041, P.R.China
3. State Key Laboratory of Biological Treatment of West China Hospital, Sichuan University, Chengdu, 610041, P.R.China
- Publication Type:Journal Article
- Keywords:
Fibroblast growth factor 21;
atherosclerosis;
biomarker
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2018;25(5):434-439
- CountryChina
- Language:Chinese
-
Abstract:
Fibroblast growth factor 21 (FGF21) is a multi-effect endocrine factor, mainly secreted in liver and adipose tissue, with the properties of lipid-lowering, anti-inflammatory, anti-oxidant and anti-atherosclerosis. Recent studies found that FGF21 can induce protective effect in cardiovascular disease, and plasma FGF21 levels in patients with disease cardiovascular are elevated. These studies have suggested the use of FGF21 as a biomarker for subclinical atherosclerosis and its potential role in the treatment of established atherosclerotic cardiovascular disease. This article will review the recent advances in the anti-atherosclerosis effect of FGF21.
